{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:35:50Z","timestamp":1761561350389},"reference-count":28,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the seroprevalence of hepatitis B (HBV) and C (HCV) in patients living in France with recent-onset polyarthritis suggesting rheumatoid arthritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The 813 patients in the ESPOIR cohort were screened for anti-HCV antibodies and HBs antigen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Seroprevalence was 0.86% for HCV (n = 7) and 0.12% for HBV (n = 1). HCV-related arthritis was diagnosed in 4 (0.5%) patients; no patient had HBV-related arthritis. HCV-seropositive patients had significantly higher transaminase levels (ALAT, 41.5 IU vs 23.2 IU, p = 0.02; and ASAT, 39.2 IU vs 21.8 IU, p = 0.001) but only 2 patients had ASAT or ALAT levels &gt; 40 IU. No significant differences were found for anti-CCP antibodies, C-reactive protein, erythrocyte sedimentation rate, or other test. HCV seroprevalence was significantly higher in the subgroup with history of blood transfusion than in other patients (3.7% vs 0.42%, p = 0.02). Two of the 7 HCV positive patients and the single patient with confirmed hepatitis B infection were born in areas with higher prevalence of viral hepatitis (Togo, Senegal, Vietnam). Positive hepatitis status was known before study inclusion in 4 of the 7 HCV-positive patients and in the HBV-positive patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The prevalence of HBV and HCV in a population of patients with recent-onset polyarthritis suggestive of RA was not greater than expected based on data from the general population in the same geographic area. Routine HBV and HCV serological testing did not contribute substantially to the diagnosis of recent-onset polyarthritis. Although advisable before initiating immunosuppressive or hepatotoxic drugs, serological testing for HCV and HBV is unnecessary in routine diagnostic evaluation of recent-onset polyarthritis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.081308","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T02:00:51Z","timestamp":1245204051000},"page":"1407-1413","source":"Crossref","is-referenced-by-count":19,"title":["Is Screening for Hepatitis B and Hepatitis C Useful in Patients with Recent-Onset Polyarthritis? The ESPOIR Cohort Study"],"prefix":"10.3899","volume":"36","author":[{"given":"XAVIER","family":"GUENNOC","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VAL\u00c9RIE","family":"NARBONNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SANDRINE","family":"JOUSSE-JOULIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VALERIE","family":"DEVAUCHELLE-PENSEC","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAXIME","family":"DOUGADOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JEAN PIERRE","family":"DAUR\u00c8S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ALAIN","family":"SARAUX","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2009,6,16]]},"reference":[{"key":"2018112909200065000_36.7.1407.1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2480"},{"key":"2018112909200065000_36.7.1407.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.10.897"},{"key":"2018112909200065000_36.7.1407.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.20527"},{"key":"2018112909200065000_36.7.1407.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.7.635"},{"key":"2018112909200065000_36.7.1407.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.06.001"},{"issue":"suppl 1","key":"2018112909200065000_36.7.1407.6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0399-077X(00)88858-7","article-title":"Epid\u00e9miologie de l\u2019h\u00e9patite C","volume":"30","author":"Roudot-Thoraval","year":"2000","journal-title":"Med Mal Infect"},{"key":"2018112909200065000_36.7.1407.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260233"},{"key":"2018112909200065000_36.7.1407.8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250630"},{"key":"2018112909200065000_36.7.1407.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(06)74575-4"},{"key":"2018112909200065000_36.7.1407.10","unstructured":"CETAF, INVS, CPAM . Estimation des taux de pr\u00e9valence des anticorps anti-VHC et des marqueurs du virus de l\u2019h\u00e9patite B chez les assur\u00e9s sociaux du r\u00e9gime g\u00e9n\u00e9ral de France m\u00e9tropolitaine, 2003\u20132004, 2005. [Internet; accessed April 19, 2009.] Available from: http:\/\/www.invs.sante.fr\/publications\/2005."},{"key":"2018112909200065000_36.7.1407.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.05.029"},{"key":"2018112909200065000_36.7.1407.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.21182"},{"key":"2018112909200065000_36.7.1407.13","first-page":"420","article-title":"Arthritis in patients with chronic hepatitis C virus infection","volume":"26","author":"Rivera","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909200065000_36.7.1407.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/30.6.455"},{"key":"2018112909200065000_36.7.1407.15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1590\/S0100-879X2005000500020","article-title":"Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies","volume":"38","author":"Barbosa","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"2018112909200065000_36.7.1407.16","first-page":"103","article-title":"Anti-hepatitis C virus antibodies in primary Sjogren\u2019s syndrome: false positive results are related to hyper-gamma-globulinaemia","volume":"10","author":"Vitali","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909200065000_36.7.1407.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.01.007"},{"key":"2018112909200065000_36.7.1407.18","first-page":"375","article-title":"Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Hagiyama","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909200065000_36.7.1407.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.686"},{"key":"2018112909200065000_36.7.1407.20","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q"},{"key":"2018112909200065000_36.7.1407.21","first-page":"2037","article-title":"Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy","volume":"25","author":"Narvaez","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909200065000_36.7.1407.22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","article-title":"Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy","volume":"112","author":"Flowers","year":"1990","journal-title":"Ann Intern Med"},{"key":"2018112909200065000_36.7.1407.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.04.001"},{"key":"2018112909200065000_36.7.1407.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.02.005"},{"key":"2018112909200065000_36.7.1407.25","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909200065000_36.7.1407.26","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.3.599"},{"key":"2018112909200065000_36.7.1407.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07451.x"},{"key":"2018112909200065000_36.7.1407.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2006.00779.x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.081308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:28:48Z","timestamp":1543512528000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.081308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,16]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.3899\/jrheum.081308"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.081308","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,16]]}}}